Wednesday, June 10, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 34 of 1,261
  1. US 12337019

    Vehicles for applying bacteria to skin, scalp, and hair

    Northwestern University Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  2. US 12338199

    Bis-octahydrophenanthrene carboxamides and protein conjugates thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  3. US 12337199

    Stable antibody formulation

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  4. US 12337017

    Microbiota transfer therapy for Pitt Hopkins Syndrome

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  5. US 12336974

    Methods and compositions for preventing and treating auditory dysfunctions

    United States Government as represented by the Department of Veterans Affairs Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  6. US 12336985

    Methods for shrinking pituitary tumors

    Corcept Therapeutics Incorporated Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  7. US 12336990

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  8. US 12338249

    Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-Nβ€²-methoxyurea

    Takeda Pharmaceutical Company Limited Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  9. US 12336980

    Dosing regimen for a selective S1P1 receptor agonist

    VANDA PHARMACEUTICALS INC. Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  10. US 12336835

    Neuromodulation to target glucose transporter and/or incretin pathways

    GE Precision Healthcare LLC Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  11. US 12338439

    Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  12. US 12338438

    Conjugated oligonucleotide compounds, methods of making and uses thereof

    E-Therapeutics PLC Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  13. US 12336973

    Cancer therapeutic compositions and methods targeting DNAse1L3

    Providence Health & Servicesβ€”Oregon Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  14. US 12338437

    OPA1 antisense oligomers for treatment of conditions and diseases

    STOKE THERAPEUTICS, INC. Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  15. US 12337020

    Bacteriophage compositions

    Takeda Pharmaceutical Company Limited Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  16. US 12338450

    Gene therapy constructs for treating Wilson disease

    Ultragenyx Pharmaceutical Inc. Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  17. US 12338274

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jun 24, 2025 Β· Expires Jun 19, 2045

    granted
  18. US 2025195525

    ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OF SYSTEMIC DISEASES IN CATS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] Β· Granted Jun 19, 2025 Β· Expires Jun 14, 2045

    granted
  19. IT 202300027246

    Matrici farmaceutiche per il rilascio prolungato di farmaci

    ANGELINI PHARMA S P A [IT] Β· Granted Jun 19, 2025 Β· Expires Jun 14, 2045

    granted
  20. WO 2025125508

    COMBINAISONS DE CORTEXOLONE-17ΑLPHA-PROPIONATE POUR LE TRAITEMENT DE L'ACNÉ

    CASSIOPEA S P A [IT] Β· Granted Jun 19, 2025 Β· Expires Jun 14, 2045

    granted
  21. WO 2025126115

    DÉGRADATION DE L'IRAK4 PAR CONJUGAISON D'INHIBITEURS D'IRAK4 AVEC DES LIGANDS DE LIGASE E3 ET PROCÉDÉS D'UTILISATION

    BEIGENE SWITZERLAND GMBH [CH] Β· Granted Jun 19, 2025 Β· Expires Jun 14, 2045

    granted
  22. US 12329816

    Immunotherapy with metabolic enzyme expression

    THE TRUSTEES OF PRINCETON UNIVERSITY Β· Granted Jun 17, 2025 Β· Expires Jun 12, 2045

    granted
  23. US 12329824

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. Β· Granted Jun 17, 2025 Β· Expires Jun 12, 2045

    granted
  24. US 12329756

    Regulation of eIF4E activity for migraine therapy

    The Board of Regents of the University of Texas System Β· Granted Jun 17, 2025 Β· Expires Jun 12, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.